|
 |
Nicardipine HydrochlorideThis page contains recent news articles, when available, and an overview of Nicardipine Hydrochloride but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.About Cardene IV Formulated with the anti-hypertensive agent nicardipine hydrochloride and originally approved by FDA in 1992, Cardene® IV is a calcium ion ... Reuters … Premixed Double Concentration Cardene® IV (nicardipine hydrochlorid... - Dec 10, 2008 Cardene® IV is a patented formulation of the anti-hypertensive agent nicardipine hydrochloride. Originally approved by FDA in 1992, Cardene IV is a calcium ... International Business Times EKR Therapeutics Receives Approval for Ready-to-Use Intravenous - Aug 1, 2008 The 200 ml RTU bags contain 20 mg of the anti-hypertensive agent nicardipine hydrochloride (0.1 mg/ml) in either dextrose or sodium chloride. ... Bloomberg Competitors by Product Report - Aug 2, 2008 Amlodipine Besylate; Diltiazem Hydrochloride; Felodipine Extended Release; Nicardipine Hydrochloride; Verapamil Hydrochloride/Verapamil Hydrochloride ER ... $75.00 - Revere - Alacra Store Competitors by Product Report - Dec 16, 2006 Amlodipine Besylate; Diltiazem Hydrochloride; Nicardipine Hydrochloride; Verapamil Hydrochloride/Verapamil Hydrochloride ER ... $75.00 - Revere Reports - Revere Competitors by Product Report - Aug 2, 2008 Amlodipine Besylate; Diltiazem Hydrochloride; Felodipine Extended Release; Nicardipine Hydrochloride; Verapamil Hydrochloride/Verapamil Hydrochloride ER ... $75.00 - Revere Reports - Revere Amneal laying foundation for growth.(Generic Drugs)(Amneal … - Oct 22, 2007 Those products are acebutolol hydrochloride capsules, flecainide acetate tablets, guanfacine hydrochloride tablets, nicardipine hydrochloride capsules and ... Free with registration - Chain Drug Review - AccessMyLibrary.com Federal Register 2007 - 72 FR 57579 Mylan Laboratories and E. Merck … - Oct 10, 2007 ...hydrochloride tablets; (4) nicardipine hydrochloride capsules; and (5) sotalol hydrochloride AF tablets to Amneal Pharmaceuticals LLC ("Amneal"). ... Pay-Per-View - Federal Register 2007 - Loislaw DNA hydrogels: Fishy fluorescence - Dec 17, 2008 As the hydrogel slowly released nicardipine hydrochloride in a slightly acidic environment, its fluorescence was recovered. The researchers conclude that ... Nature.com EKR Therapeutics Broadens Its Ready-to-Use Cardene(R) IV Product … - Nov 11, 2008 These patented 200 ml ready-to-use (RTU) intravenous bags contain 40 mg of the calcium channel blocker nicardipine hydrochloride (0.2 mg/ml) in either ... Genetic Engineering News - Genetic Engineering News (press release) US FTC OKs Mylan buy of German Merck generics unit - Sep 27, 2007 The drugs include four hypertension treatments: acebutolol hydrochloride, sotalol hydrochloride AF, guanfacine hydrochloride and nicardipine hydrochloride. ... Reuters The acquisition of Merck unit would triple Mylan's size - Sep 28, 2007 The blood pressure drugs to be divested include acebutolol hydrochloride capsules, guanfacine hydrochloride tablets, nicardipine hydrochloride capsules and ... Pittsburgh Post-Gazette - Pittsburgh Post Gazette Competitors by Product Report - Sep 30, 2006 Amlodipine Besylate; Diltiazem Hydrochloride; Nicardipine Hydrochloride; Verapamil Hydrochloride/Verapamil Hydrochloride ER ... $75.00 - Revere Reports - Revere Treatment shown to aid victims of strokes - Jun 21, 2006 The single-center study, conducted at the UMDNJ-New Jersey Medical School in Newark, showed that the drug - nicardipine hydrochloride - safely reduced blood ... Pay-Per-View - Star-Ledger - Factiva, from Dow Jones Competitors by Product Report - Mar 29, 2008 Amlodipine Besylate; Diltiazem Hydrochloride; Diltiazem Hydrochloride Extended Release; Nicardipine Hydrochloride; Verapamil Hydrochloride/Verapamil ... $75.00 - Revere Reports - Revere Protein Design to acquire ESP Pharma. - Jan 1, 2005 Cardene IV (nicardipine hydrochloride injection). Indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. ... Free with registration - BIOTECH Patent News - AccessMyLibrary.com PDL's Buyout Of ESP Pharma: $475M For Drugs, Sales Team - Jan 26, 2005 ESP, of Edison, NJ, brings to the table Cardene IV (nicardipine hydrochloride), for short-term treatment of hypertension when oral therapy is not feasible. ... BioWorld Online - BioWorld Online Teva Introduces Nicardipine HCl Injection in the United States; - Sep 22, 2008 2008 Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the introduction of Nicardipine Hydrochloride Injection, 2.5 mg/mL, ... Bloomberg Merger and Acquisition Scenario - May 19, 2007 Target (Total: 235). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere Protein Design Labs Becomes PDL BioPharma. - Jan 9, 2006 The company now markets Cardene(R) IV (nicardipine hydrochloride) for short-term treatment of hypertension when oral therapy is not feasible or desirable, ... Free with registration - PR Newswire - AccessMyLibrary.com PDL to Acquire ESP Pharma, Inc. - Jan 25, 2005 Cardene IV (nicardipine hydrochloride injection). Indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. ... $4.95 - PR Newswire - ECNext Roche Gives Up Daclizumab; PDL Seeking Asthma Partner - Nov 27, 2006 PDL, of Freemont, Calif., also gets income from marketed products such as the calcium channel blocker Cardene (nicardipine hydrochloride), ... BioWorld Online - BioWorld Online Mergers & Acquisitions; Medical laboratory acquires pharmaceutical … - Feb 21, 2005 Cardene IV (nicardipine hydrochloride injection). Indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. ... Pay-Per-View - Clinical Oncology Week - Factiva, from Dow Jones Merger and Acquisition Scenario - Nov 25, 2006 Buyer (Total: 231). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere Article: Protein Design to acquire ESP Pharma. - BIOTECH Patent News... - Jan 1, 2005 Edison, N.J., brings to the table Cardene IV (nicardipine hydrochloride), for short ... York, acted as financial adviser to ESP Pharma. ... Pay-Per-View - BIOTECH Patent News - HighBeam Research Merger and Acquisition Scenario - Dec 16, 2006 Buyer (Total: 231). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere EKR Therapeutics and PDL BioPharma Sign Asset Purchase Agreement … - Feb 4, 2008 ...to PDL's cardiovascular products, consisting of Cardene(R) IV (nicardipine hydrochloride), Cardene SR(R) and new formulations of Cardene in development, ... Lifescience-online Merger and Acquisition Scenario - May 19, 2007 Buyer (Total: 235). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 6, 2006 Target (Total: 237). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Bumex (Bumetanide) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 7, 2007 Buyer (Total: 235). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere PDL BioPharma Completes Sale of Cardiovascular Products to EKR … - Mar 10, 2008 ...consisting of Cardene® IV (nicardipine hydrochloride), Cardene SR® and new formulations of Cardene in development, as well as Retavase® (reteplase) and ... Lifescience-online Merger and Acquisition Scenario - Jan 27, 2007 Buyer (Total: 231). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere Speak with other shareholders about: (NASDAQ: ACAP), (OTCBB: NILR), … - Mar 10, 2008 ...consisting of Cardene IV (nicardipine hydrochloride), Cardene SR and new formulations of Cardene in development, as well as Retavase (reteplase) and the ... Free with registration - M2 Presswire - AccessMyLibrary.com Merger and Acquisition Scenario - Jun 16, 2007 Buyer (Total: 238). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 11, 2006 Buyer (Total: 237). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Bumex (Bumetanide) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 5, 2007 Buyer (Total: 235). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 16, 2006 Buyer (Total: 231). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere EKR Therapeutics Appoints Co-Founder Richard DeSimone as COO - Mar 27, 2008 The Company's growing portfolio of specialty acute-care products includes Cardene(R) IV (nicardipine hydrochloride), Cardene SR(R), Retavase(R) (reteplase ... Genetic Engineering News - Genetic Engineering News (press release) Merger and Acquisition Scenario - May 13, 2006 Buyer (Total: 237). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Bumex (Bumetanide) ... $250.00 - Revere Reports - Revere URGENT Study Provides Important New Insight into the Use of Dyspnea … - Jul 16, 2008 The Company's growing portfolio of specialty acute-care products includes Cardene(R) IV (nicardipine hydrochloride), Cardene SR(R), Retavase(R) (reteplase ... Genetic Engineering News - Genetic Engineering News (press release) Merger and Acquisition Scenario - Aug 19, 2006 Target (Total: 230). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 15, 2006 Buyer (Total: 237). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Bumex (Bumetanide) ... $250.00 - Revere Reports - Revere FTC одобрила Ñ?делку между Mylan Laboratories и Merck KGaA - Oct 1, 2007 Ðто 4 гипотензивных Ñ?редÑ?тва acebutolol hydrochloride, sotalol hydrochloride AF, guanfacine hydrochloride и nicardipine hydrochloride, ... ФармацевтичеÑ?кий веÑ?тник Merger and Acquisition Scenario - Mar 8, 2008 Buyer (Total: 258). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 19, 2006 Buyer (Total: 230). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 1, 2006 Retavase (Reteplase); Ularitide; Cardene I.V. (Nicardipine Hydrochloride); Nuvion (Visilizumab). Target. ABX-PTH (ABX10241); Panitumumab (ABX-EGF) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jan 26, 2008 Buyer (Total: 256). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Bumex (Bumetanide) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Feb 9, 2008 Target (Total: 258). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 8, 2006 Retavase (Reteplase); Ularitide; Cardene I.V. (Nicardipine Hydrochloride); Nuvion (Visilizumab). Target. Charles River Consulting And Staffing Services ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 4, 2006 Buyer (Total: 231). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Demadex (Torsemide) ... $250.00 - Revere Reports - Revere Press Release: Incremental Direct Expenditure of Treating Hypertension... - Aug 15, 2006 28 ... nicardipine hydrochloride) in the United States. Cardene SR capsules, the ... The efficacy of Cardene SR in treating hypertension was demonstrated in ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Jan 26, 2008 Buyer (Total: 256). Xolair (Omalizumab); Cardene (Nicardipine Hydrochloride); Dilatrend (Carvedilol); Bumex (Bumetanide) ... $250.00 - Revere Reports - Revere Press Release: Protein Design Labs Becomes PDL BioPharma. - PR … - Jan 9, 2006 The company now markets Cardene(R) IV (nicardipine hydrochloride) for short-term treatment of hypertension when oral therapy is not feasible or desirable, ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Apr 1, 2006 Retavase (Reteplase); Ularitide; Cardene I.V. (Nicardipine Hydrochloride); Nuvion (Visilizumab). Target. Covance Commercialization Consulting Services ... $250.00 - Revere Reports - Revere |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |